Derms on Drugs

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines. We’re joined by CSU expert Dr. Jason Hawkes to discuss: -How Dupixent i...

Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty. This week, we break down: Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis The future of autoimmune disease treatment: genetically modified T cells What policies people actually support (and will pay for) to reduce...

Ever feel overwhelmed by the flood of alopecia treatments and supplements? Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers. In this episode, we tackle: Which labs to order for telogen effluvium Which hair loss supplements are actually worth recommending The truth about red light helmets...

Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them.  Derms on Drugs to the rescue.  In part one of our deep dive into hair loss we cover three big topics:  1) What supplements for hair loss actually work?  You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't h...

Join Derms on Drugs for a must-hear episode packed with practical dermatology updates! Discover if Nutrafol Acne delivers, which skin care ingredients top cosmetic dermatologists swear by, and the latest breakthroughs for hand eczema. Plus, is Zoryve Foam a game-changer for psoriasis? And what’s the deal with PRAME staining for benign nevi? Get actionable insights to elevate your practice along wi...

 Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician. Derms on Drugs is...

Join Derms on Drugs for a riveting dive into artificial intelligence and automated skin cancer detection. World-renowned expert Dr. Laura Ferris, with 20 years in the field, breaks down cutting-edge research and predicts the future of dermatology. Will AI "terminate" dermatologists or empower us to focus on complex cases and patient care? Expect fresh insights, practical takeaways, and lively bant...

Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo? Plus, discove...

Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outsi...

Buckle up for a whirlwind tour of the hottest dermatology literature. This week, we’ve got the deets on: Cutaneous squamous cell carcinoma: What predicts when it'll go rogue and metastasize? Spoiler: It’s not just bad vibes. Oral lichen planus: Turns out, its cancer risk is sneakier than a derm resident dodging clinic. Remibrutinib for CSU: The first oral game-changer for chronic spontaneous urtic...

When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated? Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best derm...

Does Dupixent raise the risk of cutaneous T-cell lymphoma (CTCL) in atopic dermatitis patients? It’s the burning question gripping dermatology—and we’ve got answers. Join the Derms on Drugs team as we unpack the latest with Dr. Shamir Geller, who runs a CTCL clinic at Memorial Sloan Kettering and published the first data that truly helps us understand if there is a Dupixent - CTCL link. Plus, we d...

Late-breaking abstracts from the AAD Meeting offer a sneak peek into dermatology’s future—and we’ve done the heavy lifting for you. Derms on Drugs uncovers the hottest data that will dominate the top journals and meetings in 2025: the cutting-edge for psoriasis, new Tyk2 inhibitors, new treatment for cutaneous lupus, dupilumab’s possible role in bullous pemphigoid, patient-led patch testing innova...

New Articles on causes and treatments for AKs, Melasma, Atopic Derm, Acne, Grover's and Contact Derm.  But you can't always believe what you read in a journal, and even when you can it doesn't mean it's going to help your patients.  So, sit back, relax and join the Derms on Drugs to separate fact from fiction. A systemic option for patients with tons of actinic keratoses all over their body?  If i...

The Derms on Drugs enlist the Sultan of Scratching, Dan Kaplan from the University of Pittsburgh, to answer the age- old question - should you scratch an itch or not?  Believe it or not, some of the most cutting-edge science on the planet is focusing on this question (you think they'd have better stuff to work on, but who are we to judge). The answer(s) are going to surprise you - turns out scratc...

The Captain of Compliance, The Admiral of Adherence... Whatever you want to call him, you're going to love this week's episode as the Derms on Drugs dig deep with Dr. Steve Feldman on how to help our patients actually follow through with our recommendations. Trust us, even if you've heard Dr. Feldman talk about this before, you're still not going to want to miss this. As part of our dive into the...

-Big BCCs – Debulk First or Chemo First?;  -Do Covid or the Covid Vaccine Affect the Risk of Getting a Bullous Disease? -Does Drinking Drive Melasma? But of course that’s not all: Should we be treating Strep to help our psoriasis patients get better faster? What Biologics are new on the horizon for treating linear morphea? And just how well does oral roflumilast work for psoriasis? Join us this we...

Psoriasiform Dermatitis - the Derms on Drugs take on your worst nightmare when it comes to path reports.  Dermatitis?  Psoriasis?  Both?  Neither?  We'll get into the weeds with Amber Atwater, who looked at what the final diagnoses ended up being in hundreds of patients with psoriasiform dermatitis that gives us some clues on how to approach these patients. We also review the latest work on idiopa...

We all kind of freaked out when the news broke that benzene had been detected in benzoyl peroxide. I mean, makes sense, right -benzene even  sounds  like benzoyl - how did nobody think of this before! And the lab that detected it got Zantac pulled from the market and it was even discussed at Fall Clinical..."There is no safe amount of exposure to benzene..." The final straw was when an article dro...

Litfulo for when all hope for hair seems lost...when Olumiant strikes out, can Litfulo pinch hit and save the day? Hand eczema: Did we really need a 60,000-patient study to find out who's most likely to have horrible hands? The Hand Eczema Whisperer: Jacob Thyssen joins us all the way from the University of Copenhagen for some hand-to-hand combat: What causes it, what can you do about it right now...

Is your Litfulo not pulling its weight? New research gives you the inside scoop on when to throw in the towel We’re buzzing about oral JAK inhibitors for vitiligo, but do they really outshine NBUVB alone? We’ve got the answer  And guess what? While basking in the sun might up your skin cancer risk, it turns out those rays also help you dodge death from heart disease, cancer and other nasty surpris...

Buckle-up Kids.  Our Derms on Drugs are answering some of the hottest questions in dermatology again this week: Melanoma's Mental Massacre: Discover which patients are most likely to spiral into anxiety and depression after diagnosis and how we can help save their sanity! Biosimilar Backstabbing: Why do patients switched to biosimilars fare worse than newbies to psoriasis? We'll peel back the laye...

Buckle up! We're diving deep into the wild world of dermatology, where the only thing more dangerous than a weird mole is a boxed warning. Here's what's cooking in this episode: Rinvoq vs. Dupixent: Two drugs enter, one drug leaves! We break down this pharmaceutical cage match and wonder if we learned anything besides how to pronounce "upadacitinib." Actinic keratoses get a g...